

Partnering for the next pandemic: SAS + READDI

October 26, 2023



**Bold action now,
because the next
pandemic is
inevitable**



- Deadly new viruses are emerging more frequently.
- Vaccines end pandemics, but are reactive not proactive.
- Antiviral drugs — pills swallowed with a drink of water — offer first-line defense to reduce illness, hospitalization and death.



**Deployed on Day 1,
antivirals can slow and
even stop a viral
outbreak.**



The Solution is READDI

READDI's innovative business model breaks the panic-neglect cycle of pandemic response by proactively discovering and developing antiviral drugs BEFORE the next virus creates another global catastrophe.



Regional Partners



CHIMERIX



SGC



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



NCCU



Duke
UNIVERSITY



>30 academic, biotech, and pharma collaborators globally

Funders



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



Precision Medicine – Transforming Antiviral Treatment






THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



READDI + SAS

Phase 1 key findings





COVID-19 is a heterogeneous disease

Exploring EHR records can reveal new subtypes of pathophysiology




UNC-CH and SAS methodology identifies biomarkers of severe COVID-19




Multi-modal AI and discovery


Tracheal
aspirate



Peripheral
blood



EHR



Open data



Transcriptomics



Proteomics



Metabolomics

What's Next

